IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells

Science Translational Medicine

Volumn 3, Issue 78, 2011, Pages

  Furuta, Saori ^a,b   Jeng, Yung Ming ^a,c   Zhou, Longen ^a   Huang, Lan ^a   Kuhn, Irene ^b   Bissell, Mina J ^b   Lee, Wen Hwa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DEATH RECEPTOR; INTERLEUKIN 25; INTERLEUKIN 25 RECEPTOR; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG; FADD PROTEIN, HUMAN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; INTERLEUKIN 17; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL LINE; DRUG EFFECT; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; METABOLISM; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTERLEUKIN-17; RECEPTORS, INTERLEUKIN; RNA, SMALL INTERFERING; TANDEM MASS SPECTROMETRY; TNF RECEPTOR-ASSOCIATED DEATH DOMAIN PROTEIN;

EID: 79954536472     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001374     Document Type: Article

References (31)

1. S. Furuta, J. M. Wang, S. Wei, Y. M. Jeng, X. Jiang, B. Gu, P. L. Chen, E. Y. Lee, W. H. Lee, Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell 10, 13-24 (2006).
2. X. L. Bourhis, R. A. Toillon, B. Boilly, H. Hondermarck, Autocrine and paracrine growth inhibitors of breast cancer cells. Breast Cancer Res. Treat. 60, 251-258 (2000).
3. S. H. Barsky, N. J. Karlin, Myoepithelial cells: Autocrine and paracrine suppressors of breast cancer progression. J. Mammary Gland Biol. Neoplasia 10, 249-260 (2005).
4. T. Gudjonsson, L. Rønnov-Jessen, R. Villadsen, F. Rank, M. J. Bissell, O. W. Petersen, Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J. Cell Sci. 115, 39-50 (2002).
5. S. Furuta, X. Jiang, B. Gu, E. Cheng, P. L. Chen, W. H. Lee, Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 102, 9176-9181 (2005).
6. V. M. Weaver, O. W. Petersen, F. Wang, C. A. Larabell, P. Briand, C. Damsky, M. J. Bissell, Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245 (1997).
7. S. K. Muthuswamy, D. Li, S. Lelievre, M. J. Bissell, J. S. Brugge, ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat. Cell Biol. 3, 785-792 (2001).
8. X. Wang, C. F. Chen, P. R. Baker, P. L. Chen, P. Kaiser, L. Huang, Mass spectrometric characterization of the affinity-purified human 26S proteasome complex. Biochemistry 46, 3553-3565 (2007).
9. Y. Cao, A. Lundwall, V. Gadaleanu, H. Lilja, A. Bjartell, Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. Am. J. Pathol. 161, 2053-2063 (2002).
10. S. Kalkunte, L. Brard, C. O. Granai, N. Swamy, Inhibition of angiogenesis by vitamin D-binding protein: Characterization of anti-endothelial activity of DBP-maf. Angiogenesis 8, 349-360 (2005).
11. J. Lee, W. H. Ho,M.Maruoka, R. T. Corpuz, D. T. Baldwin, J. S. Foster, A. D. Goddard, D. G. Yansura, R. L. Vandlen, W. I. Wood, A. L. Gurney, IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J. Biol. Chem. 276, 1660-1664 (2001).
12. S. Kumar, C. R. Hanning, M. R. Brigham-Burke, D. J. Rieman, R. Lehr, S. Khandekar, R. B. Kirkpatrick, G. F. Scott, J. C. Lee, F. J. Lynch, W. Gao, A. Gambotto, M. T. Lotze, Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ production. Cytokine 18, 61-71 (2002).
13. P. M. Smallwood, I. Munoz-Sanjuan, P. Tong, J. P. Macke, S. H. Hendry, D. J. Gilbert, N. G. Copeland, N. A. Jenkins, J. Nathans, Fibroblast growth factor (FGF) homologous factors: New members of the FGF family implicated in nervous system development. Proc. Natl. Acad. Sci. U.S.A. 93, 9850-9857 (1996).
14. H. Chen, S. Shi, L. Acosta, W. Li, J. Lu, S. Bao, Z. Chen, Z. Yang, M. D. Schneider, K. R. Chien, S. J. Conway, M. C. Yoder, L. S. Haneline, D. Franco, W. Shou, BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development 131, 2219-2231 (2004).
15. S. Furuta, unpublished material.
16. J. K. Kolls, A. Lindén, Interleukin-17 family members and inflammation. Immunity 21, 467-476 (2004).
17. R. M. Neve, K. Chin, J. Fridlyand, J. Yeh, F. L. Baehner, T. Fevr, L. Clark, N. Bayani, J. P. Coppe, F. Tong, T. Speed, P. T. Spellman, S. DeVries, A. Lapuk, N. J. Wang, W. L. Kuo, J. L. Stilwell, D. Pinkel, D. G. Albertson, F. M. Waldman, F. McCormick, R. B. Dickson, M. D. Johnson, M. Lippman, S. Ethier, A. Gazdar, J. W. Gray, A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006).
18. D. C. Allred, J. M. Harvey, M. Berardo, G. M. Clark, Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11, 155-168 (1998).
19. S. Létuvé, S. Lajoie-Kadoch, S. Audusseau, M. E. Rothenberg, P. O. Fiset, M. S. Ludwig, Q. Hamid, IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J. Allergy Clin. Immunol. 117, 590-596 (2006).
20. K. Hofmann, J. Tschopp, The death domain motif found in Fas (Apo-1) and TNF receptor is present in proteins involved in apoptosis and axonal guidance. FEBS Lett. 371, 321-323 (1995).
21. S. J. Baker, E. P. Reddy, Modulation of life and death by the TNF receptor superfamily. Oncogene 17, 3261-3270 (1998).
22. Y. Maezawa, H. Nakajima, K. Suzuki, T. Tamachi, K. Ikeda, J. Inoue, Y. Saito, I. Iwamoto, Involvement of TNF receptor-associated factor 6 in IL-25 receptor signaling. J. Immunol. 176, 1013-1018 (2006).
23. L. A. Loeb, Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075-3079 (1991).
24. M. R. Kim, R. Manoukian, R. Yeh, S. M. Silbiger, D. M. Danilenko, S. Scully, J. Sun, M. L. DeRose, M. Stolina, D. Chang, G. Y. Van, K. Clarkin, H. Q. Nguyen, Y. B. Yu, S. Jing, G. Senaldi, G. Elliott, E. S. Medlock, Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood 100, 2330-2340 (2002).
25. T. A. Moseley, D. R. Haudenschild, L. Rose, A. H. Reddi, Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 14, 155-174 (2003).
26. M. M. Fort, J. Cheung, D. Yen, J. Li, S. M. Zurawski, S. Lo, S. Menon, T. Clifford, B. Hunte, R. Lesley, T. Muchamuel, S. D. Hurst, G. Zurawski, M. W. Leach, D. M. Gorman, D. M. Rennick, IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15, 985-995 (2001).
27. C. Gu, A. Castellino, J. Y. Chan, M. V. Chao, BRE: A modulator of TNF-α action. FASEB J. 12, 1101-1108 (1998).
28. M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, S. A. Rosenberg, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
29. + T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J. Immunol. 171, 5051-5063 (2003).
30. C. A. Hudis, Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007).
31. Acknowledgments: We are grateful to C. Hines and R.Wei for providing reagents and J. Mott, A. Lo, E. Y. Lee, A. D. Borowsky, and D. Brownfield for helpful comments. We thank E. Lee and X. Tian for technical assistance and R. Baehner and L. Chan (UCSF Comprehensive Cancer Center) for pathological analyses of the second cohort. Funding: This work was supported by grants from the NIH (RO1CA94170 to W.-H.L. and GM-74830 to L.H.), the National Cancer Institute (R37CA064786, U54CA126552, R01CA057621, U54CA112970, U01CA143233, and U54CA143836 to M.J.B.), the U.S. Department of Energy (DE-AC02-05CH1123 to M.J.B.), the U.S. Department of Defense (W81XWH0810736 to M.J.B. and W81XWH-05-1-0322 to S.F.), and a physician scientist award from the National Health Research Institute in Taiwan (to Y.-M.J.). Author contributions: W.-H.L. and M.J.B. were responsible for supervising the project and helping design the experiments. I.K. contributed to designing some of the control experiments. S.F. was responsible for designing and executing most of the experiments. Y.-M.J. analyzed the first cohort of breast cancer tissue sections and patients' clinical data. L.Z. performed mouse xenograft experiments. L.H. performed liquid chromatography-tandem mass spectrometry analysis. S.F., W.-H.L., M.J.B., and I.K. contributed to writing and revising the manuscript. Competing interests: A patent (PCT/US2007/081395) has been filed related to the use of IL-25 for cancer treatment. All authors declare that they have no competing interests.